口腔鳞癌4种新辅助化疗方案的成本-效果分析

Cost-effectiveness analysis of four neoadjuvant chemotherapy schemes for oral squamous cell carcinoma

目的 :探讨口腔鳞癌 4种新辅助化疗方案所产生的经济效果。方法 :收集我院 1995 .6.-2 0 0 3 .5 .间12 2例进行了 2个疗程新辅助化疗的住院口腔鳞癌患者 ,随机分为 4组 (Ⅰ～Ⅳ ) ,Ⅰ组 :卡铂 +平阳霉素 +氨甲碟呤 (CPM ) ;Ⅱ组 :平阳霉素 +氨甲碟呤 (PM ) ;Ⅲ组 :卡铂 +5 -氟脲嘧啶 (CF) ;Ⅳ组 :平阳霉素 (P) ,应用药物经济学的成本 -效果分析方法对 4种口腔鳞癌新辅助化疗方案进行评价。结果 :两个化疗疗程后 ,Ⅰ～Ⅳ组有效率分别为 61.3 6%、5 8.0 6%、65 .3 9%、42 .86% ;成本 -效果比分别为 49.2 9、78.63、2 9.11、10 2 .10。结论 :在 4种新辅助化疗方案中 ,CF方案疗效最好而成本 -效果比最低 。

Objective:To evaluate the economic effects of four neoadjuvant chemotherapy (NACT)schemes for oral squamous cell carcinoma.Method:122 cases of oral squamous cell carcinoma, admitted from June 1995 to May 2003, were collected and divided randomly into four groups(Ⅰ～Ⅳgroups): groupsⅠ: Carboplatin+Pingyangmycin+Methotrexate(CPM); groupsⅡ: Pingyangmycin+Methotrexate(PM); groupsⅢ: Carboplatin+5-Fluorouracil(CF); groupsⅣ: Pingyangmycin(P). Data was evaluated using the pharmacoeconomic cost- effectiveness Analysis.Result:After two NACT courses, the effective rates of Ⅰ～Ⅳgroups were 61.36%?58.06%? 65.39% and42.86% respectively; the cost- effectiveness ratios were 49.29?78.63? 29.11?102.10 respectively. Conclusion Among four NACT schemes, CF scheme had the highest effective rate with the lowest cost- effectiveness ratio, therefore, CF scheme is the most rational one.